alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
<TABLE> <S> <C>

<PAGE>
<ARTICLE> 5
<LEGEND>
This schedule contains summary financial information extracted from Part 1-
Financial Information and is qualified in its entirety by reference to such
financial statements.
</LEGEND>
<MULTIPLIER> 1,000
       
<S>                             <C>
<PERIOD-TYPE>                   9-MOS
<FISCAL-YEAR-END>                          DEC-31-1995
<PERIOD-END>                               SEP-30-1995
<CASH>                                         3425588
<SECURITIES>                                         0
<RECEIVABLES>                                    28046
<ALLOWANCES>                                         0
<INVENTORY>                                      91700
<CURRENT-ASSETS>                               3615000
<PP&E>                                          472576
<DEPRECIATION>                                   68748
<TOTAL-ASSETS>                                 4153388
<CURRENT-LIABILITIES>                           126882
<BONDS>                                              0
<COMMON>                                         89282
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<OTHER-SE>                                     3937224
<TOTAL-LIABILITY-AND-EQUITY>                   4153388
<SALES>                                          48467
<TOTAL-REVENUES>                                 48467
<CGS>                                            63174
<TOTAL-COSTS>                                    63174
<OTHER-EXPENSES>                               3098033
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                   0
<INCOME-PRETAX>                              (3090023)
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                          (3090023)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                 (3093323)
<EPS-PRIMARY>                                   (0.40)
<EPS-DILUTED>                                        0
        

</TABLE>
#### The People of the State of New York, Respondent, v Rodriguece Garcia, Also Known as Carlos Rodriguez, Appellant.

Submitted July 26, 2010;

decided August 26, 2010

Motion for assignment of counsel granted and Richard M. Greenberg, Esq., Office of the Appellate Defender, 11 Park Place, Suite 1601, New York, NY 10007 assigned as counsel to the appellant on the appeal herein.
No. 99-41369 -1-

* Pursuant to 5 T H C IR . R. 47.5, the court has determined that this opinion should not be published and is not precedent except under the limited circumstances set forth in 5 TH C IR . R. 47.5.4.

IN THE UNITED STATES COURT OF APPEALS

FOR THE FIFTH CIRCUIT

No. 99-41369 Conference Calendar

TONY ROGERS, Plaintiff-Appellant,

versus ALLEN PINCHBACK; INYANG E. WILSON; KEVIN WESEMAN, Defendants-Appellees.

-------------------- Appeal from the United States District Court for the Southern District of Texas

USDC No. C-99-CV-374

-------------------- April 12, 2000 Before WIENER, DeMOSS, and PARKER, Circuit Judges.
PER CURIAM: * Tony Rogers, Texas prisoner #727683, appeals from the dismissal of his civil rights action as frivolous. He contends that the medical care he received violated the Eighth Amendment. Rogers made no nonfrivolous allegations of deliberate indifference to his serious medical needs. Estelle v. Gamble , 429 U.S. 97, 106 (1976). Rogers’s appeal is without arguable merit and is frivolous. Howard v. King , 707 F.2d 215, 219-20 (5th Cir. 1983). The district court’s dismissal of Rogers’s complaint and this court’s dismissal of the appeal as frivolousNo. 99-41369 -2- count as two “strikes” for purposes of 28 U.S.C. § 1915(g). See Adepegba v. Hammons , 103 F.3d 383, 385-87 (5th Cir. 1996). Rogers is CAUTIONED that if he accumulates three “strikes” under § 1915(g), he will not be able to proceed in forma pauperis (IFP) in any civil action or appeal filed while he is incarcerated or detained in any facility unless he is under imminent danger of serious physical injury. See § 1915(g).
APPEAL DISMISSED; SANCTIONS WARNING ISSUED.
regarding the decision to enter a guilty plea, a petitioner must 

demonstrate a reasonable probability that, but for counsel's errors, 

petitioner would not have pleaded guilty and would have insisted on going 

to trial. Hill v. Lockhart, 474 U.S. 52, 58-59 (1985); Kirksey v. State, 112 

Nev. 980, 988, 923 P.2d 1102, 1107 (1996). Both components of the 

inquiry must be shown, Strickland, 466 U.S. at 697, and the petitioner 

must demonstrate the underlying facts by a preponderance of the 

evidence, Means v. State, 120 Nev. 1001, 1012, 103 P.3d 25, 33 (2004). 

First, appellant claimed that his trial counsel was ineffective 

for promising him probation. Appellant claimed that he does not speak 

English well and his counsel took advantage of the language barrier in 

advising appellant to accept the plea negotiations. Appellant failed to 

demonstrate that his counsel's performance was deficient or that he was 

prejudiced. The written guilty plea agreement, which appellant 

acknowledged was read to him in Spanish, contained no promise of 

probation and appellant affirmatively acknowledged that sentencing was 

left to the discretion of the district court and no promises not contained in 

the plea agreement had been made. The written guilty plea agreement 

further informed him of the potential consequences of the plea. Appellant 

was personally canvassed by the district court and informed sentencing 

decisions were left to the district court's discretion. Therefore, we 

conclude that the district court did not err in denying this claim. 

Second, appellant claimed that his trial counsel failed to 

inform him about his right to a direct appeal. Appellant's claim is not 

supported by the record. Appellant expressly waived his right to appeal 

the conviction in the guilty plea agreement, which appellant acknowledged 

SUPREME COURT 

OF 

NEVADA 2 

(Oj 1947A 
was read to him in Spanish. Therefore, the district court did not err in 

denying this claim. Accordingly, we 

ORDER the judgment of the district court AFFIRMED. 

Saitta 

cc: Hon. Douglas W. Herndon, District Judge 

Luis Arnoldo Lopez 

Attorney General/Carson City 

Clark County District Attorney 

Eighth District Court Clerk 

SUPREME COURT 

OF 

NEVADA 3 

(0) 1947A cep
[Federal Register Volume 74, Number 100 (Wednesday, May 27, 2009)]
[Notices]
[Page 25246]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: E9-12197]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Eunice Kennedy Shriver National Institute of Child Health & Human 
Development; Notice of Closed Meeting

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended (5 U.S.C. App.), notice is hereby given of the following 
meeting.
    The meeting will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The grant applications and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the grant applications, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: National Institute of Child Health and Human 
Development Initial Review Group; Obstetrics and Maternal-Fetal 
Biology Subcommittee.
    Date: June 15, 2009.
    Time: 9 a.m. to 5 p.m.
    Agenda: To review and evaluate grant applications.
    Place: Gaithersburg Marriott Washingtonian Center, 9751 
Washingtonian Boulevard, Gaithersburg, MD 20878.
    Contact Person: Gopal M. Bhatnagar, PhD, Scientific Review 
Administrator, National Institute of Child Health and Human 
Development, National Institutes of Health, 6100 Executive 
Boulevard, Rm 5B01, Rockville, MD 20852, (301) 435-6889, 
<a href="/cdn-cgi/l/email-protection#d2b0bab3a6bcb3b5b592bfb3bbbefcbcbbbafcb5bda4"><span class="__cf_email__" data-cfemail="e2808a83968c838585a28f838b8ecc8c8b8acc858d94">[email protected]</span></a>.

(Catalogue of Federal Domestic Assistance Program Nos. 93.864, 
Population Research; 93.865, Research for Mothers and Children; 
93.929, Center for Medical Rehabilitation Research; 93.209, 
Contraception and Infertility Loan Repayment Program, National 
Institutes of Health, HHS)

    Dated: May 15, 2009.
Jennifer Spaeth,
Director, Office of Federal Advisory Committee Policy.
[FR Doc. E9-12197 Filed 5-26-09; 8:45 am]
BILLING CODE 4140-01-P


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>
EXHIBIT 32.2



CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,



AS ADOPTED PURSUANT TO



SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002



In connection with the Quarterly Report on Form 10-QSB of Bio-Imaging Technologies, Inc. (the Company) for the quarter ended September 30,
2003 as filed with the Securities and Exchange Commission on the date hereof (the Report), the undersigned, Ted Kaminer, Senior Vice President and Chief Financial Officer of the Company, hereby certifies, pursuant to 18 U.S.C. Section
1350, that:



(1) The Report fully complies with the requirements of Section
13(a) or 15(d) of the Securities Exchange Act of 1934; and



(2) The information
contained in the Report fairly presents, in all material respects, the financial condition and results of operations of Bio-Imaging Technologies, Inc.



|                         |  | /s/ Ted Kaminer*                            
|------------------------ |  | --------------------------------------------
|Dated: November 14, 2003 |  | Ted Kaminer, Senior Vice President and Chief
|                         |  | Financial Officer                           
|                         |  | (Principal Financial and Accounting Officer)

---

|* | A signed original of this written statement required by Section 906 has been provided to us and will be retained by us and furnished to the Securities and Exchange Commission or its
staff upon request.
|- | ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
* Pursuant to Local Rule 47.5, the court has determined

that this opinion should not be published and is not precedent except under the limited circumstances set forth in Local Rule 47.5.4. IN THE UNITED STATES COURT OF APPEALS FOR THE FIFTH CIRCUIT

No. 97-40929 Conference Calendar

UNITED STATES OF AMERICA, Plaintiff-Appellee,

versus DAVID MEEKS, Defendant-Appellant.

- - - - - - - - - - Appeal from the United States District Court for the Eastern District of Texas USDC No. 6:96-CR-26-1

- - - - - - - - - - February 11, 1998 Before SMITH, EMILIO M. GARZA, and DeMOSS, Circuit Judges. PER CURIAM: * David Meeks appeals his sentence following his guilty-plea conviction for possession with the intent to distribute crack cocaine. He argues that the disparate sentencing provisions for crack cocaine and cocain powder contained in the Sentencing Guidelines offend the Equal Protection and Due Process Clauses of the Constitution.No. 97-40929 - 2 - We have reviewed the record and the briefs of the parties and find no reversible error in Meeks’s sentence. See United States v. Meeks , No. 6:96CR00026-001 (E.D. Tex. July 29, 1997). Because Meeks’s argument of error is wholly without merit, this appeal is frivolous and is DISMISSED. See Howard v. King , 707 F.2d 215, 219-20 (5th Cir. 1983); 5th Cir. R. 42.2.
II 

111TH CONGRESS 

1ST SESSION S. 2480 

To suspend temporarily the duty on certain hot feed extruding equipment 

used in the manufacture of extra-wide pneumatic truck and automobile 

tires, and parts and accessories thereof. 

IN THE SENATE OF THE UNITED STATES 

OCTOBER 29, 2009 

Mr. GRAHAM introduced the following bill; which was read twice and referred 

to the Committee on Finance 

A BILL 

To suspend temporarily the duty on certain hot feed extruding equipment used in the manufacture of extra-wide 

pneumatic truck and automobile tires, and parts and 

accessories thereof. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. CERTAIN HOT FEED EXTRUDING EQUIPMENT 

4 USED IN THE MANUFACTURE OF EXTRA-WIDE 

5 PNEUMATIC TRUCK AND AUTOMOBILE TIRES, 

6 AND PARTS AND ACCESSORIES THEREOF. 

7 (a) IN GENERAL.—Subchapter II of chapter 99 of 

8 the Harmonized Tariff Schedule of the United States is 


jbell on DSKDVH8Z91PROD with BILLS
2 

•S 2480 IS

1 amended by inserting in numerical sequence the following 

2 new heading: 

‘‘ 9902.01.00 Hot feed extruding machines 

certified by the importer as 

for building truck and automobile tires, such machines 

capable of extruding rubber 

materials measuring 870 mm 

or more but not over 1200 

mm in width, and parts 

thereof (provided for in subheading 8477.20.00, 

8477.90.25, 8477.90.45, or 

8477.90.85) ........................... Free No change No change On or before 

12/31/2011 ’’. 

3 (b) EFFECTIVE DATE.—The amendment made by 

4 subsection (a) applies to articles entered, or withdrawn 

5 from warehouse for consumption, on or after the 15th day 

6 after the date of the enactment of this Act. 

Æ 


jbell on DSKDVH8Z91PROD with BILLS
II 

111TH CONGRESS 

1ST SESSION S. 2672 

To suspend temporarily the duty on copper oxychloride and copper hydroxide. 

IN THE SENATE OF THE UNITED STATES 

NOVEMBER 2, 2009 

Mr. BURR introduced the following bill; which was read twice and referred to 

the Committee on Finance 

A BILL 

To suspend temporarily the duty on copper oxychloride and 

copper hydroxide. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. COPPER OXYCHLORIDE AND COPPER HYDROX4 IDE. 

5 (a) IN GENERAL.—Subchapter II of chapter 99 of 

6 the Harmonized Tariff Schedule of the United States is 

7 amended by inserting in numerical sequence the following 

8 new heading: 

‘‘ 9902.01.00 Copper oxychloride (CAS No. 

2042–59–2) and copper hydroxide (CAS No. 1332–40– 

7) (provided for in subheading 3808.92.30) ............. Free No change No change On or before 

12/31/2011 ’’. 


jbell on DSKDVH8Z91PROD with BILLS
2 

•S 2672 IS

1 (b) EFFECTIVE DATE.—The amendment made by 

2 subsection (a) applies to articles entered, or withdrawn 

3 from warehouse for consumption, on or after the 15th day 

4 after the date of the enactment of this Act. 

Æ 


jbell on DSKDVH8Z91PROD with BILLS
<TABLE> <S> <C>

<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM
BOOKS-A-MILLION INC. CONSOLIDATED BALANCE SHEETS, CONSOLIDATED STATEMENTS OF
INCOME AND CONSOLIDATED STATEMENTS OF CASH FLOWS AND IS QUALIFIED IN ITS 
ENTIRETY BY REFERENCE TO SUCH FORM 10-K FOR THE PERIOD ENDED FEBRUARY 1, 1997.
</LEGEND>
<RESTATED> 
<MULTIPLIER> 1,000
<CURRENCY> U.S. DOLLARS
       
<S>                             <C>
<PERIOD-TYPE>                   YEAR
<FISCAL-YEAR-END>                          FEB-01-1997
<PERIOD-START>                             FEB-04-1996
<PERIOD-END>                               FEB-01-1997
<EXCHANGE-RATE>                                      1
<CASH>                                           4,776
<SECURITIES>                                         0
<RECEIVABLES>                                   19,382
<ALLOWANCES>                                       330
<INVENTORY>                                    141,430
<CURRENT-ASSETS>                               168,755<F1>
<PP&E>                                          90,820
<DEPRECIATION>                                  27,673
<TOTAL-ASSETS>                                 233,539<F2>
<CURRENT-LIABILITIES>                           98,126
<BONDS>                                              0<F3>
<PREFERRED-MANDATORY>                                0<F4>
<PREFERRED>                                          0
<COMMON>                                           174
<OTHER-SE>                                      96,246
<TOTAL-LIABILITY-AND-EQUITY>                   233,539
<SALES>                                        278,613
<TOTAL-REVENUES>                               278,613
<CGS>                                          206,269
<TOTAL-COSTS>                                  256,905
<OTHER-EXPENSES>                                 9,540
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                               2,826
<INCOME-PRETAX>                                  9,342
<INCOME-TAX>                                     3,550
<INCOME-CONTINUING>                              5,792
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                     5,792
<EPS-PRIMARY>                                     0.33<F5>
<EPS-DILUTED>                                     0.33<F5>
<FN>
<F1><OTHER CURRENT ASSETS>       3,497        OTHER CURRENT ASSETS
<F2><OTHER ASSETS>               1,637        OTHER ASSETS
<F3><LONG TERM DEBT>            37,645        LONG TERM DEBT
<F4><DEFERRED INCOME TAXES>      1,348        DEFERRED INCOME TAXES
<F5>THE EARNINGS PER SHARE CALCULATIONS HAVE BEEN PREPARED IN ACCORDANCE WITH SFAS
NO. 128 AND BASIC AND DILUTED EARNINGS PER SHARE HAVE BEEN ENTERED IN PLACE OF
PRIMARY AND FULLY DILUTED, RESPECTIVELY.
</FN>
        

</TABLE>
# SEAT Cost Summary

National On Call

 Exclusive Use

USFS

USFS

BLM

State

NPS

BIA

FWS

BLM

State

NPS

BIA

FWS

STATE Exclusive Use

# Sheet2

# Sheet3
February 4, 2023              TRANSLATIONAL            

Naoko Mizuno, Ph.D.

|

Laboratory of Structural Cell Biology

|

## Description

The virus SARS-CoV-2 is highly pathogenic because of the way its spike protein (S protein) interacts with host-cell receptors. The disease it causes, COVID-19, is often associated with low platelet counts and excessive blood clotting, leading to myocardial infarction in severe cases. This study employed electron cryotomography (CryoET)—an imaging technique used to produce high-resolution three-dimensional views of biological macromolecules and cells—to offer a direct observation of the interaction between S proteins and platelets. The authors reported that this interaction triggers platelet deformation in some instances, which leads to their irreversible activation and in rare cases, the excessive blood clotting seen in severe COVID-19 cases. 

## What is exciting about this article?

The abnormal blood clotting seen in severe COVID-19 cases may lead to cardiovascular complications, respiratory failure, and multiple organ failures. In this study, the researchers found that SARS-CoV-2 spike protein binds to platelet integrin receptors to trigger platelet deformation. Exposure to S protein also primed these blood cells for activation upon exposure to additional stimuli that are also active during infection, leading to rare but severe blood coagulation in critical cases.

## How does this fit into the larger NIAMS portfolio?

The goal of Dr. Mizuno's research is to understand the molecular mechanisms of dynamic morphological changes in platelets. This article not only sheds light on how SARS-CoV-2 infection leads to abnormal thrombosis, but also demonstrates the power of direct imaging at molecular resolution.

## Grant support

HL006264

Research Areas:
Cell BiologyStructural Biology

Reference:

###             Direct Cryo-ET observation of platelet deformation induced by SARS-CoV-2 spike protein.        

14(1).

Research reported in this publication was supported by the Intramural Research Program of the NIHʼs National Institute of Arthritis and Musculoskeletal and Skin Diseases.

Previous

See All Advances

Next

## Recent Advances

Selected recent highlights of NIAMS intramural research:

October 3, 2023

The Transcription Factor STAT4 Controls the Fate of Cytotoxic Innate Lymphocytes

September 26, 2023

Genetic Variants of PLCG2 Cause Immune Dysregulation Through Either Increased or Decreased Function

September 26, 2023

The Microbiomes of People with Recombination-Activating Gene (RAG) Deficiency Have Distinct Features, Including Antimicrobial Resistance Signatures 

September 23, 2023

Neutrophil Extracellular Traps (NETs) Trigger Pathogenic Inflammation and Bone Loss in Periodontitis

September 22, 2023

Possible Mechanism of a Rare Bone Overgrowth Disease Identified

Back to Top
#### In the Matter of Shellfish, Inc., Appellant, v New York State Department of Environmental Conservation et al., Respondents.

Submitted November 8, 2010;

decided January 18, 2011

On the Court’s own motion, appeal dismissed, without costs, upon the ground that no substantial constitutional question is directly involved. Motion for leave to appeal denied.
EXHIBIT 99.1



                         CERTIFICATION PURSUANT TO
                          18 U.S.C. SECTION 1350,
                          AS ADOPTED PURSUANT TO
                SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002



In connection with the Quarterly Report of Yocream International, Inc. (the
Company) on Form 10-Q for the quarter ended April 30, 2003 as filed with the
Securities and Exchange Commission on the date hereof (the Report), I, John
N. Hanna, Director, Chairman, and Chief Executive Officer of the Company,
certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906
of the Sarbanes-Oxley Act of 2002, that:

       (1) The Report fully complies with the requirements of section 13(a)
or 15(d) of the Securities Exchange Act of 1934; and

       (2) The information contained in the Report fairly presents, in all
material respects, the financial condition and result of operations of the
Company.



/s/ John N. Hanna
-----------------
John N. Hanna
Chairman and Chief Executive Officer
Yocream International, Inc.
June 13, 2003
##### 



Exhibit 32.2 Written Statement of Vice Chairman and Chief Financial Officer

Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. Section
1350) The undersigned, the Vice Chairman and Chief Financial Officer of Orbital
Sciences Corporation (the Company), hereby certifies that, to his
knowledge, on the date hereof:  (a)
    
    the Quarterly Report on Form 10-Q of the Company for the
Quarter Ended September 30, 2004 filed on the date hereof with the
Securities and Exchange Commission (the Report) fully complies
with the requirements of Section 13(a) or 15(d) of the Securities
Exchange Act of 1934; and(b)
    
    information contained in the Report fairly presents, in all
material respects, the financial condition and results of operations
of the Company. /s/ Garrett E. PierceGarrett E. PierceVice Chairman and Chief Financial
Officer 
October 25, 2004 A signed original of this written statement required by Section 906 has
been provided to the Company and will be retained by the Company and furnished
to the Securities and Exchange Commission or its staff upon request.